The increase in exoPD-L1 during anti-PD-1 treatment is thought to result from IFN-γ stimulation produced by reinvigorated CD8+ T cells, indicating that the change in tumor-derived exoPD-L1 is an adaptive response of tumor cells to T cell regeneration (140). Here, PDCD1 is linked to neoplasm.